CXCR7 Articles


  • CXCR7: A novel tumor endothelial marker in renal cell carcinoma, "Beyond the Abstract," by Kyoko Hida, DDSc, PhD, et al.

    BERKELEY, CA ( - New blood vessels are formed from preexisting capillaries during tumor development. This process, widely known as tumor angiogenesis, sustains tumor progression under pathological conditions. The molecules involved in tumor angiogenesis are potential biomarkers and targets of pharmacological intervention.[1, 2] An anti-vascular endothelial growth factor (VEGF) treatment used in patients with metastatic colon cancer validates the therapeutic value of tumor antiangiogenic intervention.[3, 4] Inhibition of VEGF-dependent angiogenesis combined with chemotherapy is clearly effective under some pathological conditions; however, its effectiveness is limited[5, 6] suggesting that the characterization of alternative molecular new targets is essential for developing novel antiangiogenic therapeutic tools. Several theoretical factors have been used for targeting tumor vasculatures as anticancer strategies. We previously reported that tumor endothelial cells (TECs) differ from normal endothelial cells (NECs) in terms of characteristics such as cell proliferation, migration, gene profile[7], and responses to growth factors[7, 8] or various chemotherapeutic drugs. Furthermore, TECs were cytogenetically abnormal.

    Published December 5, 2012
  • Effect of CXCL12 and Its Receptors on Unpredictable Renal Cell Carcinoma.

    Chemokines are chemotactic cytokines that participate in numerous cell functions during hematopoiesis, morphogenesis, inflammation, neovascularization, and autoimmune diseases and cancer. They achieve their functions on binding to their G protein-coupled receptors.

    Published January 9, 2020
  • Enzalutamide and CXCR7 inhibitor Combination Treatment Suppresses Cell Growth and Angiogenic Signaling in Castration-Resistant Prostate Cancer Models.

    Previous studies have shown that increased levels of chemokine receptor CXCR7 are associated with the increased invasiveness of prostate cancer cells. We now show that CXCR7 expression is upregulated in VCaP and C4-2B cells after enzalutamide (ENZ) treatment.

    Published January 3, 2018